Agreement Regarding Expiration and Refund of Exclusive License Between Oregon Health & Science University and Regen BioPharma, Inc.

Contract Categories: Intellectual Property › License Agreements
Summary

Oregon Health & Science University (OHSU) and Regen BioPharma, Inc. agree that their Exclusive License Agreement, dated June 5, 2013, has expired because the relevant patent is no longer active. OHSU will refund Regen BioPharma the $35,000 previously paid under the license and will void an outstanding invoice of $9,167.31. Regen BioPharma must confirm acceptance of these terms by signing the letter. This agreement finalizes the end of the license and related financial obligations.

View More
EX-10.1 3 exh10_1.htm EXHIBIT 10.1 exh10_1.htm
 
Exhibit 10.1
 
 


 
Oregon Health & Science UniversityTECHNOLOGY TRANSFER AND BUSINESS DEVELOPMENT
0690 SW Bancroft Street Portland, Oregon 97239 Phone : 503 ###-###-#### Fax: 503 ###-###-#### Mail Code: L106TT Andrew R.O. Watson, PhD, CLP Director, Technology Transfer August 8, 2013 David Koos Chairman & CEO  Regen BioPharma, Inc. 4700 Spring St., #304 La Mesa, CA 91942
Re: Expiration of Exclusive License between Regen BioPharma and Oregon Health & Science University
Dear Mr. Koos: In reference to the Exclusive License Agreement between Oregon Health & Science University ("OHSU") and Regen BioPharma, Inc. ("Regen") dated June 5, 2013, it has come to my attention that the patent listed in Appendix A of this license (United States Patent No. 6,821,513) is no longer active. The "Term" of this license, as defined in the license, has therefore expired as no patent rights remain.
As Regen has paid OHSU a total of $35,000 to date for the rights granted by OHSU to Regen under this license and considering that no patent rights remain, OHSU is willing to refund the full $35,000 to Regen. Furthermore, OHSU Invoice No. 226423 dated 23-Jul-2013 in the amount of $9,167.31 will be voided and no longer due and payable by Regen.
Thank you for your understanding in this matter. Please confirm your acceptance of the above by signing below.
Sincerely, Andrew R.O. Watson, PhD, CLP Director, Technology Transfer Agreed and Accepted: David Koos Chairman & CEO  Regen BioPharma, Inc.  Date 8/8/2013